TerrAscend Announces Chief Financial Officer Transition Plan
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North...
Healthcare
FDA expands XENOVIEW® indication to include children from six years of age
Increases number of eligible patients by approximately one millionDURHAM, NC and LONDON, June 02, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging...
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed...
Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national...
Introducing Tempus One in the EHR with Integrated Guidelines
The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to...
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year...
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced...
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)...
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to...
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple...
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic...
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of...
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)...
Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth, Improvement in Bottom Line Results, and Delivers Strong Performance Across Verticals
“It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals,...
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today...
AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30,...
Custom Health Enters into Definitive Agreement to Complete Business Combination with Queue Ventures
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Custom Health, Inc. ("Custom Health"), a technology-enabled healthcare solutions company providing...
Vaniam Group™ Introduces Vaniam Intelligence™: Purpose-Built AI, Guided by Human Insight
CHICAGO, Ill., May 30, 2025 /PRNewswire/ -- Vaniam Group™, a leader in medical communications, is proud to announce the launch...
Provider Network Holdings Appoints Dr. Edith A. Perez, M.D. as Chief Medical Officer of Cornerstone Specialty Network
PEARLAND, Texas, May 30, 2025 /PRNewswire/ -- Cornerstone Specialty Network ("Cornerstone"), a leading provider of innovative solutions for specialty providers...
Supply Chain Leadership Acknowledged for Paving the Way for MedTech Innovation and Growth
Sanjay Gupta from Imbed Biosciences Inc. Featured in The Wall Street Journal as a Distinguished Leader in Healthcare Supply Chain...